Cargando…

Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance

OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruf, Benjamin, Roggia, Cristiana, Schroeder, Christopher, Mattern, Sven, Fend, Falko, Klag, Thomas, Götz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435617/
https://www.ncbi.nlm.nih.gov/pubmed/35499650
http://dx.doi.org/10.1007/s12029-022-00831-1
_version_ 1785092142375370752
author Ruf, Benjamin
Roggia, Cristiana
Schroeder, Christopher
Mattern, Sven
Fend, Falko
Klag, Thomas
Götz, Martin
author_facet Ruf, Benjamin
Roggia, Cristiana
Schroeder, Christopher
Mattern, Sven
Fend, Falko
Klag, Thomas
Götz, Martin
author_sort Ruf, Benjamin
collection PubMed
description OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutation are advised to undergo prophylactic gastrectomy. For patients preferring conservative management, endoscopic surveillance is recommended. The detection of diffuse gastric cancer using white light endoscopy, however, remains challenging. METHODS: Patients with pathogenic CDH1 mutation underwent (chromo)endoscopic surveillance or endoscopy prior to surgery. Biopsies were taken at suspicious sites identified by chromoendoscopy. In addition, endoscopically normal areas were assessed with mapping biopsies. Detection rates from endoscopic biopsies (mapping vs. targeted) and gastrectomy specimen were then compared. RESULT: Between 11/2015 and 12/2020, ten patients from four families with a known CDH1 germline mutation had a total of n = 24 endoscopies with n = 518 total biopsies being examined. Three patients were diagnosed with GC during the study period. These patients all had suspicious chromoendoscopic lesions (= detection rate 100%). In two of three patients who had suspicious chromoendoscopic lesions, signet cell carcinoma was also detected in mapping biopsies and multiple additional cancer foci were identified in the gastrectomy specimen. CONCLUSION: Chromoendoscopy facilitated detection of gastric carcinoma foci in CDH1 mutation carriers. Chromoendoscopy identified all patients with gastric cancer, but not all cancer foci present in these patients. We conclude that for patients opting against prophylactic total gastrectomy, the addition of chromoendoscopy to white light could be used to enhance diagnostic reliability of endoscopic surveillance.
format Online
Article
Text
id pubmed-10435617
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-104356172023-08-19 Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance Ruf, Benjamin Roggia, Cristiana Schroeder, Christopher Mattern, Sven Fend, Falko Klag, Thomas Götz, Martin J Gastrointest Cancer Original Research OBJECTIVES: Germline mutations in the CDH1-gene are identified as the cause of 30–40% of cases of hereditary diffuse gastric cancer, an autosomal-dominant inherited cancer predisposition syndrome. Given this high risk of developing diffuse gastric cancer, carriers of a pathogenic CDH1 germline mutation are advised to undergo prophylactic gastrectomy. For patients preferring conservative management, endoscopic surveillance is recommended. The detection of diffuse gastric cancer using white light endoscopy, however, remains challenging. METHODS: Patients with pathogenic CDH1 mutation underwent (chromo)endoscopic surveillance or endoscopy prior to surgery. Biopsies were taken at suspicious sites identified by chromoendoscopy. In addition, endoscopically normal areas were assessed with mapping biopsies. Detection rates from endoscopic biopsies (mapping vs. targeted) and gastrectomy specimen were then compared. RESULT: Between 11/2015 and 12/2020, ten patients from four families with a known CDH1 germline mutation had a total of n = 24 endoscopies with n = 518 total biopsies being examined. Three patients were diagnosed with GC during the study period. These patients all had suspicious chromoendoscopic lesions (= detection rate 100%). In two of three patients who had suspicious chromoendoscopic lesions, signet cell carcinoma was also detected in mapping biopsies and multiple additional cancer foci were identified in the gastrectomy specimen. CONCLUSION: Chromoendoscopy facilitated detection of gastric carcinoma foci in CDH1 mutation carriers. Chromoendoscopy identified all patients with gastric cancer, but not all cancer foci present in these patients. We conclude that for patients opting against prophylactic total gastrectomy, the addition of chromoendoscopy to white light could be used to enhance diagnostic reliability of endoscopic surveillance. Springer US 2022-05-02 2023 /pmc/articles/PMC10435617/ /pubmed/35499650 http://dx.doi.org/10.1007/s12029-022-00831-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Ruf, Benjamin
Roggia, Cristiana
Schroeder, Christopher
Mattern, Sven
Fend, Falko
Klag, Thomas
Götz, Martin
Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title_full Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title_fullStr Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title_full_unstemmed Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title_short Chromoendoscopy in Combination with Random Biopsies for Patients with Pathogenic CDH1 Mutations Undergoing Endoscopic Surveillance
title_sort chromoendoscopy in combination with random biopsies for patients with pathogenic cdh1 mutations undergoing endoscopic surveillance
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435617/
https://www.ncbi.nlm.nih.gov/pubmed/35499650
http://dx.doi.org/10.1007/s12029-022-00831-1
work_keys_str_mv AT rufbenjamin chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT roggiacristiana chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT schroederchristopher chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT matternsven chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT fendfalko chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT klagthomas chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance
AT gotzmartin chromoendoscopyincombinationwithrandombiopsiesforpatientswithpathogeniccdh1mutationsundergoingendoscopicsurveillance